Industry
Biotechnology
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation, and True Human COVID-19 therapy for treating the COVID-19 mutant virus. The company was incorporated in 2005 and is headquartered in Austin, Texas.
Loading...
Open
6.66
Mkt cap
208M
Volume
30K
High
7.03
P/E Ratio
-6.32
52-wk high
9.96
Low
6.54
Div yield
N/A
52-wk low
3.54
Portfolio Pulse from Vandana Singh
June 18, 2024 | 5:08 pm
Portfolio Pulse from Benzinga Newsdesk
June 18, 2024 | 3:49 pm
Portfolio Pulse from Benzinga Newsdesk
June 18, 2024 | 3:49 pm
Portfolio Pulse from Benzinga Newsdesk
June 18, 2024 | 3:48 pm
Portfolio Pulse from Benzinga Insights
January 22, 2024 | 1:06 pm
Portfolio Pulse from Benzinga Newsdesk
September 26, 2023 | 1:05 pm
Portfolio Pulse from Benzinga Insights
September 05, 2023 | 9:31 pm
Portfolio Pulse from Happy Mohamed
August 30, 2023 | 1:08 pm
Portfolio Pulse from Happy Mohamed
August 08, 2023 | 3:48 pm
Portfolio Pulse from Benzinga Newsdesk
May 22, 2023 | 1:16 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.